2017: PathoVax license on Chimeric L1/L2 Protein and Virus-Like Particles Based Human Papillomavirus Vaccines

(More on government funded inventionsĀ here. Other KEI comments on NIH licenses are foundĀ here.) On June 5, 2017, KEI provided comments to the NIH/NCI, on a prospective grant of an exclusive license to PathoVax, relating to HPV vaccines. On July 10,… Continue Reading